104 related articles for article (PubMed ID: 16205839)
21. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M
Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594
[TBL] [Abstract][Full Text] [Related]
22. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
23. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity.
Cao Z; Harris N; Kozielski A; Vardeman D; Stehlin JS; Giovanella B
J Med Chem; 1998 Jan; 41(1):31-7. PubMed ID: 9438019
[TBL] [Abstract][Full Text] [Related]
24. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationship of alkyl 9-nitrocamptothecin esters.
Cao ZS; Pantazis P; Mendoza J; Early J; Kozielski A; Harris N; Giovanella B
Acta Pharmacol Sin; 2003 Feb; 24(2):109-19. PubMed ID: 12546717
[TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.
Gliniak B; Le T
Cancer Res; 1999 Dec; 59(24):6153-8. PubMed ID: 10626806
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic/pharmacodynamic modeling of etoposide tumor growth inhibitory effect in Walker-256 tumor-bearing rat model using free intratumoral drug concentrations.
Pigatto MC; Roman RM; Carrara L; Buffon A; Magni P; Dalla Costa T
Eur J Pharm Sci; 2017 Jan; 97():70-78. PubMed ID: 27816627
[TBL] [Abstract][Full Text] [Related]
28. Anticancer potential of Hericium erinaceus extracts against human gastrointestinal cancers.
Li G; Yu K; Li F; Xu K; Li J; He S; Cao S; Tan G
J Ethnopharmacol; 2014 Apr; 153(2):521-30. PubMed ID: 24631140
[TBL] [Abstract][Full Text] [Related]
29. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
[TBL] [Abstract][Full Text] [Related]
30. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice.
Morton CL; Iacono L; Hyatt JL; Taylor KR; Cheshire PJ; Houghton PJ; Danks MK; Stewart CF; Potter PM
Cancer Chemother Pharmacol; 2005 Dec; 56(6):629-36. PubMed ID: 15918039
[TBL] [Abstract][Full Text] [Related]
31. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.
Gautam A; Waldrep JC; Densmore CL; Koshkina N; Melton S; Roberts L; Gilbert B; Knight V
Gene Ther; 2002 Mar; 9(5):353-7. PubMed ID: 11938455
[TBL] [Abstract][Full Text] [Related]
32. Translational pharmacokinetic/pharmacodynamic analysis in cancer pharmacology: a tool to maximize the value of antitumor efficacy from tumor bearing mice.
Wong H; Gould SE
Drug Discov Today Technol; 2016; 21-22():51-56. PubMed ID: 27978988
[TBL] [Abstract][Full Text] [Related]
33. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
[TBL] [Abstract][Full Text] [Related]
34. 9-Nitrocamptothecin is an effective drug for the treatment of human lung tumors: comparison of in vitro and in vivo studies.
Han Z; Wyche JH; Sands H; Pantazis P
Anticancer Res; 2001; 21(3B):1823-7. PubMed ID: 11497265
[TBL] [Abstract][Full Text] [Related]
35. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect.
Silver DF; Piver MS
Gynecol Oncol; 1999 May; 73(2):280-4. PubMed ID: 10329047
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro.
Pantazis P; Early JA; Mendoza JT; DeJesus AR; Giovanella BC
Cancer Res; 1994 Feb; 54(3):771-6. PubMed ID: 8306340
[TBL] [Abstract][Full Text] [Related]
37. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
38. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
Narla RK; Chen CL; Dong Y; Uckun FM
Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
[TBL] [Abstract][Full Text] [Related]
39. [In vitro and in vivo stability of 9-nitrocamptothecin lactone form in rats].
Chen J; Ping QN; Guo JX; Liu L; Chu XZ; Song MM
Yao Xue Xue Bao; 2005 Oct; 40(10):888-92. PubMed ID: 16408803
[TBL] [Abstract][Full Text] [Related]
40. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.
Gong IY; Teft WA; Ly J; Chen YH; Alicke B; Kim RB; Choo EF
Breast Cancer Res Treat; 2013 May; 139(1):61-9. PubMed ID: 23605084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
